Your browser is no longer supported. Please, upgrade your browser.
Settings
MNTA Momenta Pharmaceuticals, Inc. daily Stock Chart
MNTA [NASD]
Momenta Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.36 Insider Own0.40% Shs Outstand99.50M Perf Week9.07%
Market Cap1.40B Forward P/E- EPS next Y-1.89 Insider Trans-32.21% Shs Float97.65M Perf Month19.24%
Income-217.40M PEG- EPS next Q-0.51 Inst Own99.10% Short Float4.27% Perf Quarter11.67%
Sales67.00M P/S20.89 EPS this Y-87.80% Inst Trans-0.82% Short Ratio7.60 Perf Half Y-3.17%
Book/sh3.17 P/B4.44 EPS next Y27.00% ROA-45.20% Target Price23.00 Perf Year-48.37%
Cash/sh2.72 P/C5.18 EPS next 5Y- ROE-60.20% 52W Range9.51 - 29.30 Perf YTD27.45%
Dividend- P/FCF- EPS past 5Y-1.20% ROI-39.30% 52W High-51.98% Beta2.04
Dividend %- Quick Ratio7.60 Sales past 5Y16.30% Gross Margin- 52W Low47.95% ATR0.57
Employees131 Current Ratio7.60 Sales Q/Q-60.00% Oper. Margin- RSI (14)69.46 Volatility4.91% 4.47%
OptionableYes Debt/Eq0.00 EPS Q/Q-26.60% Profit Margin- Rel Volume0.56 Prev Close13.76
ShortableYes LT Debt/Eq0.00 EarningsAug 02 BMO Payout- Avg Volume548.31K Price14.07
Recom2.40 SMA2010.23% SMA5019.84% SMA20012.32% Volume306,491 Change2.25%
Jan-04-19Downgrade JP Morgan Overweight → Neutral
Nov-05-18Initiated Piper Jaffray Overweight
Feb-22-18Upgrade Stifel Hold → Buy $18 → $21
Oct-05-17Downgrade Stifel Buy → Hold $22 → $15
Sep-28-17Initiated Goldman Neutral $18
May-22-17Downgrade Barclays Overweight → Equal Weight $20 → $17
Feb-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Jan-31-17Reiterated Barclays Overweight $19 → $20
Nov-22-16Initiated Aegis Capital Hold
Oct-11-16Upgrade Barclays Equal Weight → Overweight $13 → $19
Sep-07-16Downgrade Maxim Group Hold → Sell $6
Jun-06-16Initiated Goldman Neutral $14
Jan-08-16Upgrade Maxim Group Sell → Hold
Nov-13-15Initiated JP Morgan Overweight
Aug-06-15Downgrade Goldman Buy → Neutral
Jun-19-15Reiterated Stifel Buy $26 → $29
Jun-19-15Reiterated Brean Capital Buy $25 → $31
Jun-04-15Initiated Stifel Buy $26
Apr-17-15Reiterated Leerink Partners Outperform $16 → $24
Apr-17-15Reiterated Brean Capital Buy $15 → $25
Sep-16-19 01:32PM  Is Momenta Pharmaceuticals, Inc.'s (NASDAQ:MNTA) CEO Paid At A Competitive Rate? Simply Wall St.
Sep-01-19 09:30AM  Momenta (MNTA) Up 10% Since Last Earnings Report: Can It Continue? Zacks
Aug-08-19 03:45PM  Momenta Continues Its Transition Motley Fool
07:17AM  Edited Transcript of MNTA earnings conference call or presentation 2-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-05-19 04:35PM  Momenta Pharmaceuticals Inc (MNTA) Q2 2019 Earnings Call Transcript Motley Fool
10:59AM  Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss Zacks
Aug-02-19 08:25AM  Momenta Pharmaceuticals (MNTA) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:00AM  Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results GlobeNewswire
Aug-01-19 04:05PM  Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation GlobeNewswire
Jul-30-19 07:00AM  Momenta Pharmaceuticals Announces Fast Track Designation for M281 (nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN) GlobeNewswire +5.83%
Jul-26-19 10:30AM  Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-19-19 08:00AM  Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast GlobeNewswire -5.42%
Jun-19-19 08:00AM  Momenta Pharmaceuticals Announces Settlement Agreement with Amphastar Resolving Enoxaparin Sodium Injection Litigation GlobeNewswire
Jun-17-19 03:54PM  Did You Manage To Avoid Momenta Pharmaceuticals's (NASDAQ:MNTA) 47% Share Price Drop? Simply Wall St. +5.18%
Jun-04-19 07:30AM  Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 40th Annual Global Healthcare Conference GlobeNewswire
Jun-01-19 09:31AM  Momenta (MNTA) Down 16.6% Since Last Earnings Report: Can It Rebound? Zacks
May-28-19 03:39PM  Edited Transcript of MNTA earnings conference call or presentation 2-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-09-19 08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference GlobeNewswire
May-07-19 03:41PM  Momenta Pharmaceuticals Wants to Be the "Humira of the FcRn Space" Motley Fool -8.60%
May-03-19 08:26PM  Hedge Funds Have Never Been This Bullish On Momenta Pharmaceuticals, Inc. (MNTA) Insider Monkey
May-02-19 03:16PM  Momenta Pharmaceuticals Inc (MNTA) Q1 2019 Earnings Call Transcript Motley Fool
10:05AM  Momenta Pharmaceuticals (MNTA) Reports Q1 Loss, Misses Revenue Estimates Zacks
09:01AM  Momenta: 1Q Earnings Snapshot Associated Press
07:00AM  Momenta Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results GlobeNewswire
Apr-25-19 10:33AM  Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Apr-18-19 08:00AM  Momenta Pharmaceuticals Announces Date of First Quarter 2019 Financial Results Conference Call and Webcast GlobeNewswire
Mar-29-19 07:35AM  New Research Coverage Highlights American International Group, Fox Factory Holding, Momenta Pharmaceuticals, Mercer International, Endurance International Group, and Addus HomeCare Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-28-19 07:00AM  Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019 GlobeNewswire
Mar-27-19 06:13PM  Novartis (NVS) Receives FDA Approval for MS Drug Mayzent Zacks
Mar-24-19 09:30AM  Momenta (MNTA) Down 6.8% Since Last Earnings Report: Can It Rebound? Zacks
Mar-21-19 08:43AM  Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta GlobeNewswire
Mar-12-19 11:38AM  How Should Investors React To Momenta Pharmaceuticals, Inc.s (NASDAQ:MNTA) CEO Pay? Simply Wall St.
Mar-01-19 06:38AM  Edited Transcript of MNTA earnings conference call or presentation 22-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-28-19 02:01PM  Momenta Continues to Rebuild Motley Fool
Feb-25-19 10:28AM  Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat Zacks
Feb-22-19 10:05AM  Momenta Pharmaceuticals (MNTA) Reports Q4 Loss, Tops Revenue Estimates Zacks +8.55%
06:47AM  Momenta: 4Q Earnings Snapshot Associated Press
06:30AM  Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-15-19 10:30AM  Analysts Estimate Momenta Pharmaceuticals (MNTA) to Report a Decline in Earnings: What to Look Out for Zacks +8.92%
Feb-08-19 08:00AM  Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2018 Financial Results Conference Call and Webcast GlobeNewswire +5.81%
Feb-07-19 08:00AM  Momenta Pharmaceuticals Announces Oral Presentation of New Data for M281 at the Society for Maternal-Fetal Medicine 2019 Annual Meeting GlobeNewswire
Jan-29-19 08:00AM  Momenta Pharmaceuticals Announces First Subject Dosed in Phase 1/2 Clinical Trial of M254, Hypersialylated Immunoglobulin G GlobeNewswire
Jan-23-19 07:55AM  New Research Coverage Highlights Lennox International, Momenta Pharmaceuticals, Westlake Chemical Partners LP, Symantec, American Eagle Outfitters, and FTD Companies Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Jan-07-19 01:46PM  What Investors Should Know About Momenta Pharmaceuticals, Inc.s (NASDAQ:MNTA) Financial Strength Simply Wall St. +7.83%
Jan-02-19 08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-17-18 09:41PM  Here is What Hedge Funds Think About Momenta Pharmaceuticals, Inc. (MNTA) Insider Monkey
12:38PM  Edited Transcript of MNTA earnings conference call or presentation 7-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Dec-11-18 05:06PM  Here's Why Momenta Pharmaceuticals Fell for a Second Straight Day Motley Fool -10.39%
04:05PM  Momenta Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
03:03PM  Teva (TEVA) Stock Poised to Record Big Gains in 2019? Zacks
Dec-07-18 04:23PM  Here's Why Momenta Pharmaceuticals Jumped 18% on Friday Motley Fool +17.96%
08:04AM  The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut Benzinga
Dec-06-18 08:13PM  Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire +8.15%
07:56AM  The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering Benzinga
Dec-05-18 04:15PM  Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Dec-03-18 04:05PM  Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA® GlobeNewswire
Nov-27-18 07:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Eclipse Resources, DISH Network, Navigant Consulting, TreeHouse Foods, Momenta Pharmaceuticals, and Party City Holdco New Research Emphasizes Economic Growth GlobeNewswire
Nov-17-18 08:36AM  Why Abbvie Is Down 5% in 2018 So Far Motley Fool
Nov-16-18 02:06PM  Momenta Moves On Motley Fool
Nov-09-18 03:25PM  Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3 Zacks -9.55%
Nov-07-18 12:30PM  Momenta Pharmaceuticals Inc (MNTA) Q3 2018 Earnings Conference Call Transcript Motley Fool
09:45AM  Momenta Pharmaceuticals Announces Publication of Phase 1 Study Data for Anti-FcRn Antibody, M281 GlobeNewswire
07:50AM  The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie Benzinga
07:40AM  Momenta Pharmaceuticals (MNTA) Reports Q3 Loss, Lags Revenue Estimates Zacks
06:35AM  Momenta: 3Q Earnings Snapshot Associated Press
06:00AM  Momenta Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-06-18 04:45PM  Momenta Pharmaceuticals Announces Global Settlement with AbbVie to Enable Commercialization of M923, a Proposed Biosimilar to HUMIRA® (adalimumab) GlobeNewswire
08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2018 Healthcare Conference GlobeNewswire
Oct-31-18 08:00AM  Momenta Pharmaceuticals Announces Date of Third Quarter 2018 Financial Results Conference Call and Webcast GlobeNewswire
Oct-12-18 11:00PM  Here's Why Momenta Pharmaceuticals Tumbled 13.5% on Friday Motley Fool -13.49%
04:34PM  Why PNC Financial Services Group, Wabash National, and Momenta Pharmaceuticals Slumped Today Motley Fool
Oct-11-18 06:15PM  Here's Why Momenta Pharmaceuticals Fell 11.3% on Thursday Motley Fool -11.30%
07:35AM  Recent Analysis Shows RadNet, Electro Scientific Industries, Koppers, Momenta Pharmaceuticals, IQVIA, and Columbia Property Trust Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Oct-04-18 08:00AM  Momenta Pharmaceuticals to Host R&D Day on October 11, 2018 GlobeNewswire
Oct-01-18 08:42AM  Momenta lays off 110 workers, 50% of staff, including several C-level execs American City Business Journals
08:00AM  Today's Research Reports on Trending Tickers: Momenta Pharmaceuticals and Arena Pharmaceuticals ACCESSWIRE
06:00AM  Momenta Pharmaceuticals Completes Strategic Review to Refocus its Operations and Drive Shareholder Value GlobeNewswire
Sep-19-18 08:43AM  Do Options Traders Know Something About Momenta Pharmaceuticals (MNTA) Stock We Don't? Zacks
Sep-12-18 08:00AM  Today's Research Reports on Trending Tickers: Momenta Pharmaceuticals and Aerie Pharmaceuticals ACCESSWIRE
Sep-06-18 08:00AM  Today's Research Reports on Trending Tickers: Momenta Pharmaceuticals and Supernus Pharmaceuticals ACCESSWIRE
Aug-28-18 01:50PM  Edited Transcript of MNTA earnings conference call or presentation 9-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-13-18 03:30PM  Momenta Moves Meticulously Motley Fool
Aug-10-18 02:57PM  Momenta Pharmaceuticals (MNTA) Q2 2018 Earnings Conference Call Transcript Motley Fool
08:46AM  Momenta (MNTA) Earnings and Revenues Lag Estimates in Q2 Zacks
Aug-09-18 06:16AM  Momenta: 2Q Earnings Snapshot Associated Press -7.83%
06:00AM  Momenta Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
06:00AM  Momenta Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Aug-06-18 07:50AM  Recent Analysis Shows Regis, Graco, Columbia Sportswear, Momenta Pharmaceuticals, Interface, and Bunge Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-02-18 08:00AM  Momenta Pharmaceuticals Announces Date of Second Quarter 2018 Financial Results Conference Call and Webcast GlobeNewswire
Jul-25-18 07:35AM  Free Technical Research on Evolus and Three More Generic Drugs Equities ACCESSWIRE
Jul-16-18 08:00AM  Today's Research Reports on Trending Tickers: Zogenix and Momenta Pharmaceuticals ACCESSWIRE
Jul-13-18 08:00AM  Today's Research Reports on Trending Tickers: Akorn and Momenta Pharmaceuticals ACCESSWIRE +6.26%
Jun-19-18 07:15AM  Free Stock Performance Review on Zoetis and Three Additional Generic Drugs Stocks ACCESSWIRE
Jun-06-18 04:02PM  Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 39th Annual Global Healthcare Conference GlobeNewswire
May-23-18 10:48AM  Should You Hold Momenta (MNTA) Stock in Your Portfolio? Zacks
May-17-18 04:05PM  Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity GlobeNewswire
May-15-18 01:49PM  Momenta Pharmaceuticals Contemplates Its Future Motley Fool
May-10-18 05:36AM  Edited Transcript of MNTA earnings conference call or presentation 8-May-18 12:00pm GMT Thomson Reuters StreetEvents -8.14%
May-09-18 12:10PM  Momenta Pharmaceuticals (MNTA) Q1 2018 Earnings Conference Call Transcript Motley Fool
09:01AM  Momenta (MNTA) Incurs Wider Y/Y Loss, Glatopa Sales Decline Zacks
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WHEELER CRAIG APresident & CEOAug 13Sale11.932,77833,14216,614Aug 14 04:05 PM
WHEELER CRAIG APresident & CEOAug 12Option Exercise0.006,172019,392Aug 14 04:05 PM
Manning Anthony M.Chief Scientific OfficerAug 12Sale11.641141,3277,390Aug 13 05:04 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerAug 12Sale11.645336,20469,290Aug 13 05:05 PM
FIER IANChief Mfg and Program OfficerAug 12Sale11.643544,1215,015Aug 13 05:04 PM
KWON YOUNGSVP, Chief Business OfficerAug 12Sale11.645336,204100,819Aug 13 05:03 PM
WHEELER CRAIG APresident & CEOAug 12Sale11.741,77320,81513,220Aug 13 05:02 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerAug 08Sale11.825987,06869,833Aug 09 04:18 PM
Manning Anthony M.Chief Scientific OfficerAug 08Sale11.822212,6127,509Aug 09 04:19 PM
WHEELER CRAIG APresident & CEOAug 08Sale11.722,60130,48414,993Aug 09 04:20 PM
KWON YOUNGSVP, Chief Business OfficerAug 08Sale11.826267,399101,362Aug 09 04:20 PM
FIER IANChief Mfg and Program OfficerAug 08Sale11.822102,4825,374Aug 09 04:19 PM
FIER IANChief Mfg and Program OfficerAug 07Option Exercise0.0071305,584Aug 09 04:19 PM
KWON YOUNGSVP, Chief Business OfficerAug 07Option Exercise0.001,4090101,988Aug 09 04:20 PM
WHEELER CRAIG APresident & CEOAug 07Option Exercise0.005,781017,594Aug 09 04:20 PM
Manning Anthony M.Chief Scientific OfficerAug 07Option Exercise0.0075007,730Aug 09 04:19 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerAug 07Option Exercise0.001,346070,431Aug 09 04:18 PM
DOWNEY BRUCEDirectorJun 20Option Exercise0.004,356032,590Jun 21 04:17 PM
Fishman Corey N.DirectorJun 20Option Exercise0.004,356010,090Jun 21 04:16 PM
Gutierrez-Ramos Jose-CarlosDirectorJun 20Option Exercise0.004,356010,090Jun 21 04:15 PM
GILMAN STEVEN CDirectorJun 20Option Exercise0.004,35607,796Jun 21 04:15 PM
GEMAYEL GEORGESDirectorJun 20Option Exercise0.004,356014,090Jun 21 04:16 PM
SULAT JAMES RDirectorJun 20Option Exercise0.004,356054,090Jun 21 04:14 PM
Stoner ElizabethDirectorJun 20Option Exercise0.004,356033,995Jun 21 04:14 PM
Koestler Thomas PDirectorJun 20Option Exercise0.004,356015,590Jun 21 04:14 PM
Manning Anthony M.Chief Scientific OfficerJun 20Sale13.0039,433512,6296,980Jun 21 04:13 PM
SULAT JAMES RDirectorMay 24Option Exercise8.8510,00088,50049,734May 29 04:12 PM
WHEELER CRAIG APresident & CEOMay 14Sale13.722,77838,11420,552May 15 06:58 PM
KWON YOUNGSVP, Chief Business OfficerMay 10Option Exercise13.262,99839,75399,518May 14 06:56 PM
FIER IANChief Mfg and Program OfficerMay 10Sale14.003544,9564,871May 14 06:55 PM
Manning Anthony M.Chief Scientific OfficerMay 10Sale14.001141,59646,413May 14 06:58 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerMay 10Sale14.003544,95669,085May 14 06:56 PM
WHEELER CRAIG APresident & CEOMay 10Sale14.131,77225,03817,158May 14 06:57 PM
KWON YOUNGSVP, Chief Business OfficerMay 10Sale14.003544,95696,520May 14 06:56 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerMay 08Sale13.684005,47269,439May 09 04:25 PM
WHEELER CRAIG APresident & CEOMay 08Sale13.982,60136,36218,930May 09 04:24 PM
Manning Anthony M.Chief Scientific OfficerMay 08Sale13.682243,06446,527May 09 04:24 PM
KWON YOUNGSVP, Chief Business OfficerMay 08Sale13.684195,73296,874May 09 04:25 PM
FIER IANChief Mfg and Program OfficerMay 08Sale13.682132,9145,225May 09 04:25 PM
Carvajal AlejandraChief Legal OfficerApr 29Sale14.7710,384153,3720May 01 04:04 PM
FIER IANChief Mfg and Program OfficerApr 29Sale15.0038,677580,1554,726May 01 04:02 PM
Arroyo SantiagoSVP, Chief Medical OfficerApr 29Sale15.002,53137,96519,272May 01 04:03 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerApr 29Sale15.0013,672205,08068,494May 01 04:02 PM
Arroyo SantiagoSVP, Chief Medical OfficerApr 09Sale15.008,119121,78539,803Apr 11 04:10 PM
FIER IANChief Mfg and Program OfficerApr 09Sale15.004,16362,44573,403Apr 11 04:10 PM
DOWNEY BRUCEDirectorMar 18Option Exercise8.8520,000177,00041,234Mar 20 04:57 PM
DOWNEY BRUCEDirectorMar 18Sale14.5113,000188,63028,234Mar 20 04:57 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerMar 18Sale14.2029,167414,171112,166Mar 19 05:07 PM
FIER IANChief Mfg and Program OfficerMar 15Sale13.9210,000139,20077,566Mar 19 04:58 PM
KWON YOUNGSVP, Chief Business OfficerFeb 20Sale14.053514,932125,883Feb 22 04:03 PM
WHEELER CRAIG APresident & CEOFeb 20Sale14.081,43520,205177,067Feb 22 04:04 PM
FIER IANChief Mfg and Program OfficerFeb 20Sale14.053514,93287,566Feb 22 04:03 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerFeb 20Sale14.054035,662141,333Feb 21 04:04 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerFeb 19Sale13.628,377114,095141,736Feb 21 04:04 PM
ROBERTSON MICHELLEChief Financial OfficerFeb 14Sale13.107039,20911,526Feb 19 04:55 PM
Manning Anthony M.Chief Scientific OfficerFeb 14Sale13.104,44958,28276,001Feb 19 04:55 PM
KWON YOUNGSVP, Chief Business OfficerFeb 14Sale13.104,45058,295126,234Feb 19 04:53 PM
Carvajal AlejandraChief Legal OfficerFeb 14Sale13.107039,20915,108Feb 19 04:52 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerFeb 14Sale13.104,45058,295150,113Feb 19 04:52 PM
FIER IANChief Mfg and Program OfficerFeb 14Sale13.104,45058,29587,917Feb 19 04:52 PM
Arroyo SantiagoSVP, Chief Medical OfficerFeb 14Sale13.102,67134,99047,922Feb 19 04:51 PM
WHEELER CRAIG APresident & CEOFeb 13Sale12.6716,875213,806178,502Feb 19 04:56 PM
Arroyo SantiagoSVP, Chief Medical OfficerFeb 13Sale12.707,74298,32350,593Feb 14 04:26 PM
Carvajal AlejandraChief Legal OfficerFeb 13Sale12.702,93837,31315,811Feb 14 04:26 PM
FIER IANChief Mfg and Program OfficerFeb 13Sale12.705,45369,25392,367Feb 14 04:27 PM
KWON YOUNGSVP, Chief Business OfficerFeb 13Sale12.708,358106,147130,684Feb 14 04:27 PM
Manning Anthony M.Chief Scientific OfficerFeb 13Sale12.707,71798,00680,450Feb 14 04:28 PM
ROBERTSON MICHELLEChief Financial OfficerFeb 13Sale12.701,41017,90712,229Feb 14 04:28 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerFeb 13Sale12.708,403106,718154,563Feb 14 04:26 PM
WHEELER CRAIG APresident & CEOFeb 13Sale12.9311,110143,652195,377Feb 13 04:43 PM
WHEELER CRAIG APresident & CEOFeb 12Sale12.841,77322,765181,800Feb 13 04:43 PM
FIER IANChief Mfg and Program OfficerFeb 12Sale12.774145,28780,320Feb 13 04:44 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerFeb 12Sale12.774145,287135,466Feb 13 04:44 PM
Manning Anthony M.Chief Scientific OfficerFeb 12Sale12.771331,69863,167Feb 13 04:43 PM
KWON YOUNGSVP, Chief Business OfficerFeb 12Sale12.774145,287111,542Feb 13 04:43 PM
Manning Anthony M.Chief Scientific OfficerFeb 08Sale11.522643,04163,300Feb 11 04:26 PM
WHEELER CRAIG APresident & CEOFeb 08Sale11.762,60130,588183,573Feb 11 04:26 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerFeb 08Sale11.524725,437135,880Feb 11 04:22 PM
FIER IANChief Mfg and Program OfficerFeb 08Sale11.522512,89280,734Feb 11 04:23 PM
KWON YOUNGSVP, Chief Business OfficerFeb 08Sale11.524945,691111,956Feb 11 04:24 PM
KWON YOUNGSVP, Chief Business OfficerNov 20Sale12.305356,581111,041Nov 21 04:24 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerNov 20Sale12.306157,565135,007Nov 21 04:23 PM
FIER IANChief Mfg and Program OfficerNov 20Sale12.303554,36780,272Nov 21 04:23 PM
WHEELER CRAIG APresident & CEONov 20Sale12.381,96924,376180,393Nov 21 04:22 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerNov 12Sale13.153524,629135,622Nov 14 04:32 PM
KWON YOUNGSVP, Chief Business OfficerNov 12Sale13.155306,970111,576Nov 14 04:31 PM
FIER IANChief Mfg and Program OfficerNov 12Sale13.153524,62980,627Nov 14 04:31 PM
Manning Anthony M.Chief Scientific OfficerNov 12Sale13.151131,48662,814Nov 14 04:31 PM
WHEELER CRAIG APresident & CEONov 12Sale12.631,77222,380182,362Nov 13 04:56 PM
WHEELER CRAIG APresident & CEONov 08Sale14.092,60236,662184,134Nov 13 04:56 PM
BELTRAMELLO JO ANNChief HR and Inf. OfficerNov 08Sale14.094095,763135,974Nov 13 04:56 PM
FIER IANChief Mfg and Program OfficerNov 08Sale14.092183,07280,979Nov 13 04:57 PM
KWON YOUNGSVP, Corporate DevelopmentNov 08Sale14.096469,102112,106Nov 13 04:55 PM
Manning Anthony M.Chief Scientific OfficerNov 08Sale14.092293,22762,927Nov 13 04:57 PM